Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Drugmaker Eli Lilly ... high cholesterol. Lilly has a strong portfolio of GLP-1 drugs that have helped propel its growth. Last quarter alone, its two leading GLP-1 drugs, Mounjaro and Zepbound ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly, which makes Zepbound and Mounjaro, reports that in a phase one clinical trial, a once daily GLP-1 pill helped lower the hemoglobin A1C, a measure of blood sugar control, in people with type ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its ...